Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuroinflammation and CNS Targeted Therapy Development
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ICAM5 (Telencephalin) drug discovery. ICAM5 is a neural-specific adhesion molecule with 5 Ig-like C2-type domains, restricted to the telencephalon. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ICAM5 ECD-Fc Fusion Protein (5 Ig-like Domains) HEK293 Expressed, Native Glycosylation, Sequence Verified, >95% Purity, Endotoxin <1 EU/µg |
View ICAM5 Products |
| Gene Delivery | ICAM5 Lentivirus Particles (Full-Length ORF) For stable cell line construction in neuronal/BBB models. CMV promoter, Puromycin selection. |
View ICAM5 Products |
| Benchmark Ab | Anti-ICAM5 Reference Antibody Recombinant chimeric positive control, Sequence Verified, Suitable for blocking and binding assays. |
View ICAM5 Products |
| Validator | ICAM5 siRNA Set (3 unique sequences) For knockdown verification and specificity controls in adhesion assays. |
View ICAM5 Products |
| Related Target (Counter-screen) | ICAM1 (CD54) Critical for off-target binding assessment within the immunoglobulin superfamily. |
View ICAM1 Products |
| Ligand Partner | ITGAL (CD11a, LFA-1 α chain) Natural ligand for ICAM5; essential for adhesion inhibition assay development. |
View ITGAL Products |
Technical Specifications for Critical Assay Challenges
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Glycosylation & Conformational Folding | HEK293 expressed (Native Glycosylation) ensuring authentic structural epitopes |
| Cross-species CNS Translation (Human/Mouse/Cyno) | Species ortholog proteins (Human, Cynomolgus, Mouse) with identical domain architecture, Sequence Verified by Mass Spec |
| Epitope Domain Mapping (D1-D2 vs D3-D5) | Truncated variants: ICAM5-D1D2 and ICAM5-D3D5 Fusions for precise epitope binning |
| ICAM Family Selectivity (Avoid ICAM1/3 cross-reactivity) | Homolog panel including ICAM1, ICAM3, and ICAM5 for specificity screening; siRNA included for target-specific validation |
| Lack of Reliable Assay Controls | Clinical Benchmark Antibodies included for standardizing SPR/BLI assays |
| Background Noise in Cell Assays | Validated siRNA included for strict specificity and false-positive checks |
| Cell-Based Adhesion & BBB Transcytosis | Lentivirus for stable ICAM5-expressing endothelial cell lines (hCMEC/D3 or bEnd.3 compatible) |
Key Genetic Variants
ICAM5 carries several reported mutations relevant to disease and polymorphism studies:
- Somatic mutations in a breast cancer sample (UniProt VAR_035515, VAR_035516)
- dbSNP rs1056538 (UniProt VAR_056046) These variants underline the importance of using sequence-verified antigens for assay development.
Live ICAM5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic potential of ICAM5 (Telencephalin) is rapidly transitioning from basic neuroscience to targeted drug development. As a telencephalon-specific adhesion molecule with extremely restricted peripheral expression, ICAM5 represents a high-value target for modulating immune cell trafficking across the blood-brain barrier (BBB) without systemic immunosuppression. Current R&D is bifurcated: one major track focuses on soluble ICAM5 (sICAM5) as a cerebrospinal fluid/serum biomarker for synaptic injury in Alzheimer's disease, traumatic brain injury, and dementia; the other track is developing anti-ICAM5 monoclonal antibodies for blocking leukocyte infiltration (via LFA-1) in neuroinflammatory diseases such as multiple sclerosis and autoimmune encephalitis, as well as exploiting neuronal-specific expression for CNS-targeted delivery vehicles (ADC, bispecific engagers). The next wave of innovation emphasizes domain-specific epitope engineering to distinguish ICAM5 from ubiquitous ICAM1/ICAM3 family members and to enable safe brain-penetrating therapeutics.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Blocking) | Academic Consortiums, CNS-Focused Biotechs | Neuroinflammation (MS, Autoimmune Encephalitis), Alzheimer's Disease | LFA-1 Adhesion Inhibition: requires high-purity ICAM5 ECD and ITGAL pairing |
| ADC (Antibody-Drug Conjugate) | Neuro-Oncology Pioneers | Glioblastoma, Brain Metastases | Internalization Assay: requires full-length Lentivirus-stable cell lines |
| Bispecific Engager | Immune Cell Redirectors | Neuroinflammation | Cross-species Reactivity: needs Human/Cyno/Mouse ortholog panel |
| CAR-T / Cell Therapy | Neuro-Immunology Labs | Primary Brain Tumors | Cell Surface Density Calibration: requires defined antigen standards |
Related Targets and Cross-Sell Opportunities
Build a comprehensive neuroimmunology research package by pairing ICAM5 reagents with:
- ICAM1 (CD54) – essential for selectivity screening.
- ITGAL (LFA-1 α) – natural ligand for functional assays.
- TREM2 – core neuroinflammation target for microglial modulation.
- APP – key Alzheimer's network partner for combined biomarker assessments.
These tools enable rigorous lead optimization and mechanistic validation across the entire ICAM5 pipeline.